Hematological Neoplasms

On August 19, 2021, Bristol Myers Squibb announced that the European Commission (EC) has granted conditional marketing authorization for Abecma (idecabtagene vicleucel; ide-cel).

On April 4th, 2024, Abecma® (idecabtagene vicleucel) received approval from the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with relapsed or refractory multiple myeloma.

CAR-T cell therapy has emerged as a novel immunocellular therapy in recent years. BCMA-targeted CAR-T cell therapy has become a standard treatment for relapsed/refractory MM, with some patients achieving the possibility of “clinical cure.”

BCMA (B-Cell Maturation Antigen) is a specific target for multiple myeloma, and therapies targeting BCMA are considered an effective approach to improve the quality of life for patients with multiple myeloma.

In addition to serving as an antibody target, GPRC5D is a promising CAR target. Introduction to a CART targeting GPRC5D.

BCMA (B-cell maturation antigen) is considered a major target for the treatment of multiple myeloma.

In February 2022, the US FDA officially approved Ciltacabtagene Autoleucel (brand name: CARVYKTI®, abbreviation: Cilta-cel) for the treatment of patients with relapsed/refractory multiple myeloma (R/R MM).

Carvykti (Ciltacabtagene Autoleucel) is a B-cell maturation antigen (BCMA)-directed genetically modified autologous T-cell immunotherapy for the treatment of adult patients with relapsed or refractory multiple myeloma after four or more prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.

Bispecific T cell engagers (TCEs) are revolutionizing the treatment of multiple myeloma (MM) patients by redirecting T cells against cancer cells.

Ciltacabtagene Autoleucel (Carvykti, cilta-cel), a chimeric antigen receptor T-cell (CAR-T) therapy targeting B-cell maturation antigen (BCMA), has been approved by the FDA on April 6, 2024, for the treatment of relapsed or refractory multiple myeloma (RRMM) in patients who have received at least one prior line of therapy, including a proteasome inhibitor (PI) and an immunomodulatory drug (IMiD), and are refractory to lenalidomide.